CANCER GENOMICS CONSORTIUM

`

Monday, August 8th, 2016

Dear members and friends of the Cancer Genomics Consortium,

We are pleased to announce that the Cancer Genomics Consortium (CGC) has joined forces with the American College of Medical Genetics (ACMG) Laboratory Quality Assurance Committee to develop standards and guidelines for the interpretation and reporting of acquired copy number variants (CNVs) and copy neutral (CN)-loss of heterozygosity (LOH) in cancer.

This effort was developed to build upon current ACMG standard and guidelines for microarray analysis (Genet Med 2013;15:484-494) to achieve a more detailed, uniform system to assign clinical significance to acquired CNVs and CN-LOH. The new guidelines will develop a process for classifying acquired variants, based on objective criteria using an evidence-based weighing system.

The project has been approved by the ACMG and CGC Board of Directors, and will be carried out by a joint expert group over the next 12 to 18 months, with input from members of both organizations. The final approved version will be published in *Genetics in Medicine* and the ACMG and CGC websites. While the proposed standards and guidelines are mainly intended for interpreting and reporting variants detected by chromosomal microarray analysis, the newly developed interpretation algorithm will also be applicable to acquired structural variants detected by next-generation sequencing as the clinical testing moves more towards this technology.

We look forward to sharing this work with the community!

Regards,

Daynna Wolff, Ph.D. FACMG
CGC President

Gordana Raca, M.D., Ph.D. FACMG
CGC President-Elect